News - United against Lafora

Important communication from Ionis to the Lafora community

11 September 2024

We are excited to share some news of great scientific and clinical relevance. Ionis Pharmaceuticals has announced the completion of a licensing agreement for ION283, their investigational drug for the treatment of Lafora disease.

Riconoscimento di un Traguardo Storico

11 September 2024

Riconoscimento di un Traguardo Storico nella Ricerca sulla Malattia di Lafora Con immensa gioia e profonda gratitudine, ci accingiamo ad annunciare un traguardo atteso per anni, segnato da un’ardente speranza e, talvolta, da un’inquietante angoscia. Tempozero desidera esprimere un sentito e rispettoso riconoscimento al Dott. Berge Minassian per il suo instancabile impegno e la dedizione […]

FIRST GOAL ACHIEVED!

12 March 2022

We have reached our first goal. Thanks to the many donations received, Tempo Zero has raised the first 50,000 euros, which will allow us to launch a specific research grant for Lafora disease in the spring. For the organization of this grant and for the project monitoring, we have asked for the support of the […]

SUPPORT RESEARCH

We need your help to raise funds for the development of a phase 1/2 (safety and efficacy) ASO drug specifically designed for Lafora disease.

DONATE NOW

Write to us